MARKET

GLMD

GLMD

Galmed Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.780
+0.030
+0.80%
After Hours: 3.780 0 0.00% 17:43 01/20 EST
OPEN
3.800
PREV CLOSE
3.750
HIGH
3.820
LOW
3.650
VOLUME
139.68K
TURNOVER
--
52 WEEK HIGH
6.44
52 WEEK LOW
2.960
MARKET CAP
80.56M
P/E (TTM)
-2.9889
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021
, /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an open-label part to its ARMOR Phase 3 reg...
PR Newswire - PRF · 12/17/2020 13:10
Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021
, /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an open-label part to its ARMOR Phase 3 reg...
PR Newswire - PRF · 12/17/2020 12:00
Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an open-label part to its ARMOR Phase 3 registrational study. ...
PR Newswire · 12/17/2020 12:00
Is Galmed Pharmaceuticals Ltd (GLMD) A Good Stock To Buy?
Insider Monkey · 12/04/2020 14:08
Is Galmed Pharmaceuticals Ltd (GLMD) A Good Stock To Buy?
In this article we will check out the progression of hedge fund sentiment towards Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think...
Insider Monkey · 12/04/2020 14:08
The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 11)
Benzinga · 11/12/2020 12:44
Galmed Pharmaceuticals Q3 EPS $(0.32) Misses $(0.30) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 6.67 percent. This is a 52.38 percent decrease over losses of $(0.21) per
Benzinga · 11/12/2020 12:07
Galmed EPS misses by $0.02
Galmed (GLMD): Q3 GAAP EPS of -$0.32 misses by $0.02.Cash and cash equivalents, restricted cash, short-term deposits and marketable debt securities of $58.7MPress Release
Seekingalpha · 11/12/2020 12:07
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GLMD. Analyze the recent business situations of Galmed Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GLMD stock price target is 17.80 with a high estimate of 29.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 7.90M
% Owned: 37.07%
Shares Outstanding: 21.31M
TypeInstitutionsShares
Increased
5
566.98K
New
10
-970.71K
Decreased
5
375.21K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.31%
Pharmaceuticals & Medical Research
-0.03%
Key Executives
President/Chief Executive Officer/Director
Allen Baharaff
Chief Financial Officer
Yohai Stenzler
Chief Operating Officer
Guy Nehemya
Chief Scientific Officer
Liat Hayardeny
Other
Tali Gorfine
Lead Director/Independent Director
David Sidransky
Director
Marshall Heinberg
Director
Ran Oren
Independent Director
Carol Brosgart
Independent Director
William Marth
Independent Director
Shmuel Nir
Independent Director
Tal Yaron-Eldar
Independent Director
Tali Yaron-Eldar
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About GLMD
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
More

Webull offers kinds of Galmed Pharmaceuticals Ltd stock information, including NASDAQ:GLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLMD stock methods without spending real money on the virtual paper trading platform.